Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
cancer vaccine
Biotech
BioNTech fades cancer vax in late-stage melanoma setting
BioNTech is not planning further trials of its BNT111 vaccine candidate in a specific late-stage refractory melanoma setting, a spokesperson said.
Zoey Becker
Oct 20, 2025 3:01pm
Evaxion stock slips on phase 2 cancer vax data
Oct 17, 2025 2:07pm
TransCode rewrites future, securing $25M and phase 3 vaccine
Oct 8, 2025 11:02am
IO lays off 50% after FDA derails cancer vaccine approval plan
Sep 29, 2025 8:55am
Nykode bets future on cancer trial after losing Genentech pact
Aug 27, 2025 8:25am
PDS reports 39 months OS in phase 2 head and neck cancer trial
Aug 25, 2025 9:00am
